As previously disclosed, on September 23, 2016, Natus Medical Incorporated (the "Company") entered into a Credit Agreement (the "Credit Agreement") by and between the Company and JP Morgan Chase Bank, NA ("JP Morgan") and Citibank, NA ("Citibank"). Under the terms of the Credit Agreement, an accordion feature allows the Company to increase the revolving credit facility available to it with one or more tranches of term loans not to exceed $75 million in aggregate principal amount.

Effective September 15, 2017, the Company exercised its rights under the accordion feature to increase the revolving credit facility available to it under the Credit Agreement by $75 million, bringing the aggregate revolving credit facility from $150 million to $225 million. In connection therewith, Wells Fargo Bank, National Association became a "Lender" under the terms of the Credit Agreement. All other terms of the Credit Agreement remain unchanged.

About Natus Medical Incorporated (NASDAQ:BABY)

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care.